The industry’s focus www.genotec-frankfurt.de/top-5-simple-virtual-deal-software-for-beginners/ is on living organisms, and the rigorously monitored standards make it a unique concern for business leaders. These characteristics make the industry an ideal place to foster innovation. They have produced major breakthroughs in agricultural yields, biofuels, and life-saving pharmaceuticals.
When you think of strategies to generate revenue biotech start-ups have numerous options. The majority choose either a technology partnership or an asset creation and out-licensing strategy. Technology partnering can result in higher revenue and lower financial risk, while strategies for asset creation and outlicensing can yield significantly higher returns. A growing number of research-stage biotechs operate an hybrid model that blends both strategies.
The people who choose a product-oriented development strategy will be successful commercially if they can get their pipeline to the right stage and also attract a significant pharmaceutical partner or investor with deep pockets. This could be expensive, however, and making sure that you balance opportunistic methods to leverage external resources with research-based decision making about homegrown projects is vital.
The “platform” model is a different option to generate revenue. It is less costly than product-oriented research, but is a risky option. In this model biotechs develop and own their own platform technology prior to teaming with pharma companies to develop a collection of drug discovery projects that target specific diseases (i.e. disease x in biology y). Advinus Therapeutics, among others have embraced this model.